This highlights the necessity for a model to promptly detect evidence of response to anti-PD-1 therapy, especially in CRC patients exhibiting POLE-driven hypermutation, who may benefit from immunotherapy. This evidence concerns the gene PDCD1 and colorectal carcinoma.